Full-Time

Senior Data Modeller II

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$110k - $150kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 3 more

More locations: San Francisco, CA, USA | Chicago, IL, USA | New York, NY, USA

This is a hybrid role, requiring some in-office presence.

Category
Data Management
Data Engineering
Data & Analytics
Required Skills
NoSQL
SQL

You match the following Tempus's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • You have domain knowledge in healthcare and informatics data.
  • You have experience and knowledge of different data modeling techniques (e.g. 3NF, dimensional (star schema), and data vault).
  • You have applied exceptional SQL skills in an enterprise data warehouse environment.
  • You have knowledge of ETL/ELT and BI architectures, concepts and frameworks, and experience implementing them.
  • You understand and can clearly articulate the long-term impacts of key decisions between database technologies (relational, MPP, NoSQL) and have experience architecting solutions across multiple technologies.
  • You have experience with data modeling tools like Erwin, Vertabelo or Lucidchart.
Responsibilities
  • Manage an enterprise data model in collaboration with clinicians, data scientists, engineers, product managers, and operators to integrate clinical data from source systems in multiple complex domains (clinical records, EHR data, ECG data, radiology, et al.).
  • Author and maintain entity-relationship diagrams, data dictionaries, API specs, and data translation documentation at multiple levels of abstraction (conceptual, logical, physical) and across multiple data store technologies (transactional, analytical).
  • Implement solutions to transform source data to a common data model
  • Collaborate with clinicians and data scientists to implement and validate feature definitions for clinical endpoints aligned with modeling priorities.
  • Implement solutions to proactively monitor data quality with traceability to source systems.
  • Evaluate completeness of source system data models and data by profiling partner data.
  • Advocate and educate engineering team members on data modeling rules, standards, and best practices.
Desired Qualifications
  • Experience with GCP architecture, particularly with BigQuery
  • Experience working with clinical and cardiovascular (echo, cath, ECG) data
  • Experience with Epic tables
  • Experience with HL7 data
  • Experience writing and debugging Python
  • Experience working with dbt
  • Implementing master, reference, or metadata management solutions

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's collaboration with Genialis enhances cancer diagnostics through RNA-based biomarker algorithms.
  • The olivia app centralizes patient data, providing actionable insights and empowering patient control.
  • FDA approval of the xT CDx test boosts Tempus's credibility in AI-driven diagnostics.

What critics are saying

  • Increased competition from AI healthcare platforms may erode Tempus's market share.
  • The olivia app faces potential data privacy and security challenges.
  • Reliance on FDA approvals could impact product rollout timelines due to regulatory delays.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids drug development by discovering novel targets and evaluating treatments.
  • Tempus's pan-cancer organoid platform enhances personalized therapeutic opportunities for cancer patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

Medical Device Network
Feb 13th, 2025
Artera partners with Tempus to expand AI cancer test access

Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.

TipRanks
Feb 13th, 2025
Tempus AI enters collaboration with Institute for Follicular Lymphoma Innovation

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation.

Hit Consultant
Jan 23rd, 2025
Tempus Ai Launches Ai-Powered Personal Health Concierge App

What You Should Know:– Tempus AI, a provider of AI-powered precision medicine launches olivia, an innovative personal health concierge app designed to revolutionize how patients manage their health information.– olivia brings together a patient’s health data from various sources, leverages AI to provide actionable insights, and empowers patients to take control of their health journey.Centralizing Health DataOlivia serves as a central hub for all of a patient’s health information. Patients can connect to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. This comprehensive data integration allows patients to access a complete and accurate picture of their health history.Actionable Insights Through AIolivia’s AI-enabled capabilities transform raw data into actionable insights. Patients can ask questions about their records, summarize their health information, and receive personalized responses based on their data. For example, a patient can ask, “Summarize my health status,” and olivia will provide a clear, concise summary of their health information.Empowering Patients to Take Control of Their HealthIn addition to centralizing data and providing actionable insights, olivia offers several other features to enhance the patient experience:Smart Profile Summary: olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team.olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface.olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface

OncLive
Jan 15th, 2025
NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

Tempus announces the national launch of FDA-approved xT CDx test.

BioPharmaTrend
Jan 8th, 2025
Tempus and Genialis Partner on RNA-Based Biomarker Algorithms

Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes.

HR Tech Wire
Jan 8th, 2025
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.

MedTech Dive
Jan 8th, 2025
Beta Bionics files for IPO, $44.7M revenue

Beta Bionics, maker of the iLet Bionic Pancreas, filed for an IPO to be listed on Nasdaq as "BBNX." The company aims to use the proceeds to expand sales, manufacturing, and develop new features. In 2024, Beta Bionics reported $44.7 million in revenue and a net loss of $36.6 million for the first nine months. The iLet pump, cleared by the FDA in 2023, is designed for Type 1 diabetes patients and requires less user input. The company plans to expand its use for Type 2 diabetes and develop a patch pump version.

Stock Titan
Jan 7th, 2025
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

Tempus to present at 43rd Annual J.P. Morgan Healthcare Conference.

MarketBeat
Dec 13th, 2024
Tidal Investments LLC Makes New $7.63 Million Investment in Tempus AI, Inc. (NASDAQ:TEM)

Tidal Investments LLC makes new $7.63 million investment in Tempus AI, Inc. (NASDAQ:TEM).

Stock Titan
Nov 12th, 2024
Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR(R)

Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR(R) platform through Molecular Profiling Integration (MPI).

Orange County Business Journal
Nov 11th, 2024
Tempus AI to Buy Ambry Genetics for $600M - Orange County Business Journal

Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm using artificial intelligence for precision medicine.Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

OncLive
Nov 7th, 2024
Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

Tempus announces the clinical launch of its Immune Profile Score algorithmic test.

Business Wire
Oct 28th, 2024
Tempus Announces Collaboration With JW Pharmaceutical to Apply Real-World Data and Biological Modeling to Enhance Early Research and Development

Tempus announces collaboration with JW Pharmaceutical to apply real-world data and biological modeling to enhance early research and development.